F-Prime

We’re excited to announce our $20M Series A to build the stablecoin backbone for the payments industry.🚀 “I spent over 50 years building the rails of today’s payments. I’ve been looking for the opportunity to invest in the platform that will power the next 50. We’re betting on Cyclops to be that platform.” said Javier Perez, Founder & Managing Partner of Global PayTech Ventures. Cyclops is the first and only platform allowing payments companies to plug into and orchestrate across all of the leading stablecoin providers at every level of the stack, in every corridor. With over 100 global licenses, and all the top solutions offered through a single API, Cyclops is the most redundant, agile and efficient offering in the market. This round was led by @NavaVentures(Kevin Chenault) with participation from Global PayTech Ventures, @coinbase Ventures, @Circle Ventures, @CastleIslandVC, @FPrimeCapital, Lasagna and @openfx_. Fortune exclusive👉fortune.com/2026/07/15/exc…

Nava Therapeutics is building next-gen lipid nanoparticles to do exactly that — targeting T cells, the kidney, and beyond. Proud to back the team as they emerge with $89M and head toward the clinic. 🧬 endpoints.news/nava-therapeut…

AJ Loiacono spent years auditing PBM contracts and found a system obscuring costs rather than lowering them. His conclusion: real change would require rebuilding from within. In 2017, he did exactly that. Now @judihealth covers 58M+ lives. Full Q&A👉fprimecapital.com/blog/behind-th…

F-Prime is honored to be named as a top investor for #GenAI & #mentalhealth in Galen Growth's 2024 report of the Health Tech 50 Core Investors. #HealthTech 50 report provides a deep dive into the top investors revolutionizing the digital health landscape: bit.ly/3Q3y267

Last week, we hosted a table at the 2025 @BIA_UK Gala and gathered our UK life sciences ecosystem for an evening of cocktails and conversation in London. It was great to see new and familiar faces and foster relationships across science and medicine. #BIAGalaDinner #healthcare

🎉 Congratulations to @MetseraInc on your @Nasdaq IPO! 🚀 We are excited to celebrate this milestone with you and are proud to support your work to accelerate the next generation of medicines for obesity and metabolic diseases. $MTSR #Healthcare #Biopharma #Obesity

Congratulations to @AtalantaTx on your Series B financing! Atalanta Therapeutics is a #biotech company developing treatments for intractable diseases of the central nervous system using RNA interference. Learn more: bit.ly/4hg8UVv

We’re excited to share the latest installment of our “Pioneering Progress” series, now live, highlighting the inspiring journey behind Lenmeldy — a groundbreaking achievement from our portfolio company, @orchard_tx. Learn more: bit.ly/4ewf7KR #healthcare #innovation

We're super excited for @notabene_id as they announce their $14.5M Series B today, led by DRW. Since we co-led the Series A alongside @jumpcapital, the crypto pre-trade compliance startup has gone from strength to strength. Read more from @PelleB: linkedin.com/pulse/building…

We're so excited to participate in @alluvialfinance's latest $4.3M funding round! The team will use this funding to accelerate institutional staking adoption and expand access to @liquid_col. Check out the full announcement here: alluvial.finance/strategic-fina…

Time is running out! #Science2Startup 2025, on May 14, provides research applicants the chance to receive mentorship from #biotech and #pharma leaders. Submit your application by November 15, to pitch your innovative #startup ideas to industry experts: bit.ly/4dqXc7P

Join host firms @FPrimeCapital, @atlasventure, @5amVentures, @OUP_VC, and RA Capital Management for the 2025 #Science2Startup symposium on Wed, May 14th! Have a groundbreaking idea for a #biotech #startup? Submit your application by Fri, Nov 15th: bit.ly/4dqXc7P

This month on Fintech Prime Time, we’ve got a quick preview of our next subsector deep dive with @sarah__lamont, while @abdulsiciid takes a look at how falling interest rates have affected publicly traded #fintech companies. Learn more: bit.ly/48rZaEc

Congratulations to AvenCell on your $112 Million Series B financing. This recent funding will facilitate the continued clinical validation of AvenCell’s proprietary switchable universal CAR-T #celltherapy platform. Learn more: bit.ly/4fcNkjm #healthcare #oncology

🎙️ Check out the latest BioHub Podcast episode! Host Max Brennan chats with @martinrgtaylor on his journey from the lab to #VentureCapital and the future of #biotech. Listen here: ◼️ Spotify: bit.ly/3NuJvu2 ◼️ YouTube: bit.ly/3Y7C1C7

Congratulations to the entire @ShiftBioscience team on successful completion of your Seed funding. The investment will accelerate the development of their AI cell simulation platform and support the creation of an IP portfolio. Learn more: bit.ly/3A30PDf

Congratulations to David Baker, Co-Founder of Sana Biotechnology, @Xaira_Thera, and @CHARMTherapeutx, on being awarded the 2024 #Nobel Prize in Chemistry “for computational protein design.” Learn more: bit.ly/3TM8oVs #Biotech #Healthcare #Innovation

Congrats to SPRY Therapeutics on securing your latest round of funding. Through this round of funding, they will be looking to build additional products for the global market in addition to expanding their U.S. sales and servicing team. Learn more: bit.ly/403aKDD

Attention #biotech entrepreneurs and researchers! Don’t miss your chance to pitch your #startup ideas at #Science2Startup 2025 to top biotech and #pharma executives, VCs, and entrepreneurs in the Boston area. Applications are due Fri, Nov 15th: bit.ly/4dqXc7P

This summer, @FPrimeCapital was excited to welcome a talented group of interns and fellows to our Cambridge office. Discover what it's like to be part of our #internship and #fellowship programs: bit.ly/4eiXEpU